Live Breaking News & Updates on Cadent Therapeutics|Page 6
Stay updated with breaking news from Cadent therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cadent Therapeutics : Enters Agreement to be Acquired by Novartis marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Novartis to buy Clal Biotech portfolio co Cadent for $770m Clal Biotechnology has a 13% stake in the US company, which is developing a portfolio of neuroscience and psychiatric drugs candidates. Pharmaceutical giant Novartis has agreed to acquire Clal Biotechnology Industries Ltd. (TASE: CBI) portfolio company Cadent Therapeutics for up to $770 million. Clal Biotechnology has a 13% stake in Cadent, which is developing a portfolio of neuroscience and psychiatric drug candidates for the treatment of cognitive, mood and movement disorders. RELATED ARTICLES Cadent will receive a $210 million upfront payment from Novartis, and up to a further $560 million in milestone payments. Clal Biotechnology, which is led by CEO Ofer Gonen, had several US companies, including Cadent Therapeutics, merged into its Israeli portfolio by its controlling shareholder Len Blavatnik, who wanted all his biotech assets to be managed by one entity. ....
Saniona AB Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3% Saniona was informed today that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3% PRESS RELEASE December 17, 2020 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced it was informed that Novartis plans to acquire Cadent Therapeutics, in which Saniona holds an ownership stake of approximately 3%. The financial impact of this potential acquisition to Saniona is not known at this time. Novartis and Cadent each announced today that Novartis intends to acquire all of the outstanding capital stock of Cadent. Upon the closing of the transaction, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $ ....
Novartis to buy Cadent Therapeutics for up to US$770m theedgemarkets.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theedgemarkets.com Daily Mail and Mail on Sunday newspapers.
Novartis to buy Cadent for up to $770 million marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.